BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $8.00 at Barclays

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its target price raised by stock analysts at Barclays from $7.00 to $8.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has an "equal weight" rating on the biotechnology company's stock. Barclays's target price suggests a potential upside of 13.39% from the company's current price.

Other research analysts have also recently issued reports about the stock. JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 6th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Royal Bank of Canada restated an "outperform" rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Finally, StockNews.com raised BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $14.67.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock traded down $0.29 during midday trading on Tuesday, reaching $7.06. 4,086,696 shares of the company were exchanged, compared to its average volume of 2,979,537. The firm's 50-day simple moving average is $7.84 and its 200-day simple moving average is $6.95. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.88. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -11.57 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analysts' expectations of $113.99 million. During the same quarter in the previous year, the company earned ($0.19) earnings per share. The company's revenue was up 35.1% on a year-over-year basis. On average, analysts forecast that BioCryst Pharmaceuticals will post -0.37 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in BCRX. Deerfield Management Company L.P. Series C increased its stake in BioCryst Pharmaceuticals by 62.9% during the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company's stock valued at $50,279,000 after purchasing an additional 3,140,804 shares during the last quarter. Kynam Capital Management LP grew its stake in BioCryst Pharmaceuticals by 41.9% during the 1st quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company's stock worth $33,160,000 after buying an additional 1,927,491 shares during the last quarter. Rice Hall James & Associates LLC grew its stake in BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock worth $16,444,000 after buying an additional 84,102 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 528.0% during the second quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company's stock valued at $6,874,000 after acquiring an additional 935,132 shares during the period. Finally, Sarissa Capital Management LP increased its stake in shares of BioCryst Pharmaceuticals by 9.4% in the first quarter. Sarissa Capital Management LP now owns 1,094,168 shares of the biotechnology company's stock valued at $5,558,000 after purchasing an additional 94,168 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.